Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | THRB | P10828 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.56 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869945 | 0.92 | TP53 (0.63) | TP53LMNATHRBMAPTPOLB | |
| SCHEMBL4868734 | 0.92 | TP53 (0.62) | TP53LMNATHRBMAPTPOLB | |
| SCHEMBL4862542 | 0.91 | AVPR2 (0.63) | TP53LMNATHRBMAPTPRMT5 | |
| SCHEMBL4869441 | 0.91 | TP53 (0.61) | TP53LMNATHRBMAPTPRMT5 | |
| SCHEMBL4863797 | 0.91 | POLB (0.65) | TP53LMNATHRBMAPTPOLB | |
| SCHEMBL1867242 | 0.90 | NPC1 (0.62) | TP53LMNAMAPTPRMT5WDR77 | |
| SCHEMBL4868521 | 0.90 | TP53 (0.63) | TP53LMNATHRBMAPT | |
| SCHEMBL4870647 | 0.89 | TP53 (0.62) | TP53LMNATHRBMAPTPOLB | |
| SCHEMBL4867135 | 0.88 | LMNA (0.60) | TP53LMNATHRBMAPTPOLB | |
| SCHEMBL4871802 | 0.88 | THRB (0.76) | TP53LMNATHRBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | claimed |
| EP-1778677-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | Ferring B.V. (NL) | 2007-05-02 | — | — | EP | claimed |
| WO-2006018443-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2006-02-23 | — | — | WO | claimed |
| US-20080194620-A1 | Use of Benzodiazepine Receptor Ligands For Combating Signs of Ageing | L'OREAL (FR) | 2008-08-14 | — | — | US | disclosed |
| US-20080194620-A1 | Use of Benzodiazepine Receptor Ligands For Combating Signs of Ageing | L'OREAL (FR) | 2008-08-14 | — | — | US | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194620-A1 | Use of Benzodiazepine Receptor Ligands For Combating Signs of Ageing | GABBR1, GABBR2, GABRA2 | TP53 3564/4885LMNA 1188/4885THRB 490/4885 |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | TP53 4170/4885LMNA 2162/4885THRB 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.